Companies Dominating the Peripheral Neuritis Treatment Market
- Eli Lilly and Company
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Abbott
- Bristol Myers Squibb Company
- Novartis AG
- Pfizer Inc.
- GSK Group of Companies
- Merck & Co., Inc.
- F. Hoffmann-La Roche Ltd
- RxFunction, Inc.
- Cipla Limited
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of peripheral neuritis treatment is assessed at USD 2.06 billion.
The peripheral neuritis treatment market size was valued at USD 1.94 billion in 2024 and is expected to reach USD 3.19 billion by 2037, expanding at around 3.9% CAGR during the forecast period i.e., between 2025-2037. The rising chronic diseases globally, and the large aging population will propel the market growth.
North America industry is predicted to account for largest revenue share by 2037, backed by presence of a large pool of diabetic patients and a burgeoning aging population in the region.
The major players in the market are Eli Lilly and Company, Abbott, Bristol Myers Squibb Company, Novartis AG, Pfizer Inc., GSK Group of Companies, Merck & Co., Inc., F. Hoffmann-La Roche Ltd, RxFunction, Inc., Cipla Limited
